Oncologie
Managementul anemiei
Agenți de stimulare a eritropoiezei
Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (se deschide o fereastră nouă)
Sursă: Ann Oncol 2018;29(Supplement_4):iv96-110.
Index: PubMed 29471514
DOI: 10.1093/annonc/mdx758
https://www.ncbi.nlm.nih.gov/pubmed/29471514 (se deschide o fereastră nouă)
High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (se deschide o fereastră nouă)
Sursă: Am J Hematol 2011;86(9):762-7.
Index: PubMed 21850658
DOI: 10.1002/ajh.22111
https://www.ncbi.nlm.nih.gov/pubmed/21850658 (se deschide o fereastră nouă)
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (se deschide o fereastră nouă)
Sursă: Acta Haematol 2007;117(3):162-7.
Index: PubMed 17148935
DOI: 10.1159/000097464
https://www.ncbi.nlm.nih.gov/pubmed/17148935 (se deschide o fereastră nouă)
Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (se deschide o fereastră nouă)
Sursă: Am J Hematol 2013;88(12):990-6.
Index: PubMed 23873823
DOI: 10.1002/ajh.23552
https://www.ncbi.nlm.nih.gov/pubmed/23873823 (se deschide o fereastră nouă)
Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (se deschide o fereastră nouă)
Sursă: J Clin Oncol 2011;29(28):3791-7.
Index: PubMed 21860000
DOI: 10.1200/JCO.2010.30.4899
https://www.ncbi.nlm.nih.gov/pubmed/21860000 (se deschide o fereastră nouă)
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (se deschide o fereastră nouă)
Sursă: Cancer 2012;118(3):848-55.
Index: PubMed 21751205
DOI: 10.1002/cncr.26341
https://www.ncbi.nlm.nih.gov/pubmed/21751205 (se deschide o fereastră nouă)
Management of anemia in cancer patients. (se deschide o fereastră nouă)
Sursă: Future Oncol 2011;7(4):507-17.
Index: PubMed 21463140
DOI: 10.2217/fon.11.24
https://www.ncbi.nlm.nih.gov/pubmed/21463140 (se deschide o fereastră nouă)
Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (se deschide o fereastră nouă)
Sursă: Acta Haematol Pol 2007;38(4):479-84.
Index: EMBASE 2008089811
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (se deschide o fereastră nouă)
Sursă: Support Care Cancer 2013;21(2):485-93.
Index: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (se deschide o fereastră nouă)
The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (se deschide o fereastră nouă)
Sursă: BJU Int 2011;108(10):1582-7.
Index: PubMed 21443653
DOI: 10.1111/j.1464-410X.2011.10173.x
https://www.ncbi.nlm.nih.gov/pubmed/21443653 (se deschide o fereastră nouă)
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (se deschide o fereastră nouă)
Sursă: J Clin Oncol 2010;28(13):2239-45.
Index: PubMed 20368566
DOI: 10.1200/JCO.2009.25.1835
https://www.ncbi.nlm.nih.gov/pubmed/20368566 (se deschide o fereastră nouă)
Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (se deschide o fereastră nouă)
Sursă: J Clin Oncol 2015;33(15):1674-9.
Index: PubMed 25870085
DOI: 10.1200/JCO.2014.57.9912
https://www.ncbi.nlm.nih.gov/pubmed/25870085 (se deschide o fereastră nouă)
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (se deschide o fereastră nouă)
Sursă: Br J Cancer 2011;105(9):1267-72.
Index: PubMed 21959870
DOI: 10.1038/bjc.2011.395
https://www.ncbi.nlm.nih.gov/pubmed/21959870 (se deschide o fereastră nouă)
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (se deschide o fereastră nouă)
Sursă: J Intern Med 2017;281(3):284-99.
Index: PubMed 27926979
DOI: 10.1111/joim.12579
https://www.ncbi.nlm.nih.gov/pubmed/27926979 (se deschide o fereastră nouă)
How I treat cancer-associated anemia. (se deschide o fereastră nouă)
Sursă: Blood 2020;136(7):801-13.
Index: PubMed 32556170
DOI: 10.1182/blood.2019004017
https://www.ncbi.nlm.nih.gov/pubmed/32556170 (se deschide o fereastră nouă)
Update on safety of ESAs in cancer-induced anemia. (se deschide o fereastră nouă)
Sursă: J Natl Compr Canc Netw 2012;10(5):659-66.
Index: PubMed 22570294
https://www.ncbi.nlm.nih.gov/pubmed/22570294 (se deschide o fereastră nouă)
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (se deschide o fereastră nouă)
Sursă: Eur J Haematol. 2023 110(4):354-61.
Index: PubMed 36480004
DOI: 10.1111/ejh.13910
https://pubmed.ncbi.nlm.nih.gov/36480004/ (se deschide o fereastră nouă)
A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (se deschide o fereastră nouă)
Sursă: Int J Hematol 2015;102(4):401-12.
Index: PubMed 26323997
DOI: 10.1007/s12185-015-1862-5
https://www.ncbi.nlm.nih.gov/pubmed/26323997 (se deschide o fereastră nouă)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (se deschide o fereastră nouă)
Sursă: Cancer 2013;119(1):107-14.
Index: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (se deschide o fereastră nouă)
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (se deschide o fereastră nouă)
Sursă: J Natl Cancer Inst 2013;105(14):1018-26.
Index: PubMed 23860204
DOI: 10.1093/jnci/djt145
https://www.ncbi.nlm.nih.gov/pubmed/23860204 (se deschide o fereastră nouă)
Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (se deschide o fereastră nouă)
Sursă: Cancer Sci 2013;104(4):481-5.
Index: PubMed 23331490
DOI: 10.1111/cas.12105
https://www.ncbi.nlm.nih.gov/pubmed/23331490 (se deschide o fereastră nouă)
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (se deschide o fereastră nouă)
Sursă: Br J Haematol 2019;184(2):134-60.
Index: PubMed 30549002
DOI: 10.1111/bjh.15707
https://www.ncbi.nlm.nih.gov/pubmed/30549002 (se deschide o fereastră nouă)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (se deschide o fereastră nouă)
Sursă: Support Care Cancer 2012;20(1):159-65.
Index: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (se deschide o fereastră nouă)
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (se deschide o fereastră nouă)
Sursă: Leuk Lymphoma. 2019;60(9):2324-7.
Index: PubMed 30773115
DOI: 10.1080/10428194.2019.1577414
https://www.ncbi.nlm.nih.gov/pubmed/30773115 (se deschide o fereastră nouă)
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (se deschide o fereastră nouă)
Sursă: Oncologist 2010;15(9):935-43.
Index: PubMed 20798194
DOI: 10.1634/theoncologist.2009-0279
https://www.ncbi.nlm.nih.gov/pubmed/20798194 (se deschide o fereastră nouă)
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (se deschide o fereastră nouă)
Sursă: Lung Cancer 2012;76(3):478-85.
Index: PubMed 22277104
DOI: 10.1016/j.lungcan.2011.12.015
https://www.ncbi.nlm.nih.gov/pubmed/22277104 (se deschide o fereastră nouă)
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (se deschide o fereastră nouă)
Sursă: Eur J Haematol 2016;97(1):33-8.
Index: PubMed 26341961
DOI: 10.1111/ejh.12679
https://www.ncbi.nlm.nih.gov/pubmed/26341961 (se deschide o fereastră nouă)
Fier intravenos
Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (se deschide o fereastră nouă)
Sursă: Ann Oncol 2018;29(Supplement_4):iv96-110.
Index: PubMed 29471514
DOI: 10.1093/annonc/mdx758
https://www.ncbi.nlm.nih.gov/pubmed/29471514 (se deschide o fereastră nouă)
Intravenous iron in oncology. (se deschide o fereastră nouă)
Sursă: J Natl Compr Canc Netw 2008;6(6):585-92.
Index: PubMed 18597712
https://www.ncbi.nlm.nih.gov/pubmed/18597712 (se deschide o fereastră nouă)
Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (se deschide o fereastră nouă)
Sursă: J Clin Med. 2022;11(14):4156.
Index: PubMed 35887920
DOI: 10.3390/jcm11144156
https://pubmed.ncbi.nlm.nih.gov/35887920/ (se deschide o fereastră nouă)
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (se deschide o fereastră nouă)
Sursă: Int J Colorectal Dis 2016;31(3):543-51.
Index: PubMed 26694926
DOI: 10.1007/s00384-015-2461-x
https://www.ncbi.nlm.nih.gov/pubmed/26694926 (se deschide o fereastră nouă)
How I treat cancer-associated anemia. (se deschide o fereastră nouă)
Sursă: Blood 2020;136(7):801-13.
Index: PubMed 32556170
DOI: 10.1182/blood.2019004017
https://www.ncbi.nlm.nih.gov/pubmed/32556170 (se deschide o fereastră nouă)
Total dose iron dextran infusion in cancer patients: is it SaFe2+? (se deschide o fereastră nouă)
Sursă: J Natl Compr Canc Netw 2012;10(5):669-76.
Index: PubMed 22570295
https://www.ncbi.nlm.nih.gov/pubmed/22570295 (se deschide o fereastră nouă)
Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (se deschide o fereastră nouă)
Sursă: Am J Hematol 2012;87(3):308-10.
Index: PubMed 22262486
DOI: 10.1002/ajh.22262
https://www.ncbi.nlm.nih.gov/pubmed/22262486 (se deschide o fereastră nouă)
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (se deschide o fereastră nouă)
Sursă: Eur J Haematol. 2023 110(4):354-61.
Index: PubMed 36480004
DOI: 10.1111/ejh.13910
https://pubmed.ncbi.nlm.nih.gov/36480004/ (se deschide o fereastră nouă)
Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (se deschide o fereastră nouă)
Sursă: Curr Oncol. 2023 24;30(9):7836-51.
Index: PubMed 37754484
DOI: 10.3390/curroncol30090569
https://pubmed.ncbi.nlm.nih.gov/37754484/ (se deschide o fereastră nouă)
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (se deschide o fereastră nouă)
Sursă: Cochrane Database Syst Rev 2016;(2):CD009624.
Index: PubMed 26845108
DOI: 10.1002/14651858.CD009624.pub2
https://www.ncbi.nlm.nih.gov/pubmed/26845108 (se deschide o fereastră nouă)
Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (se deschide o fereastră nouă)
Sursă: World J Gastroenterol 2014;20(8):1972-85.
Index: PubMed 24587673
DOI: 10.3748/wjg.v20.i8.1972
https://www.ncbi.nlm.nih.gov/pubmed/24587673 (se deschide o fereastră nouă)
Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (se deschide o fereastră nouă)
Sursă: South Asian J Cancer. 2023 15;12(2):93-9.
Index: PubMed 37969669
DOI: 10.1055/s-0043-1771445
https://pubmed.ncbi.nlm.nih.gov/37969669/ (se deschide o fereastră nouă)
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (se deschide o fereastră nouă)
Sursă: J Clin Oncol 2008;26(10):1619-25.
Index: PubMed 18375891
DOI: 10.1200/JCO.2007.12.2051
https://www.ncbi.nlm.nih.gov/pubmed/18375891 (se deschide o fereastră nouă)
Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (se deschide o fereastră nouă)
Sursă: J Cancer Res Clin Oncol 2012;138(2):179-87.
Index: PubMed 21972052
DOI: 10.1007/s00432-011-1072-3
https://www.ncbi.nlm.nih.gov/pubmed/21972052 (se deschide o fereastră nouă)
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (se deschide o fereastră nouă)
Sursă: Ann Oncol 2013;24(2):475-82.
Index: PubMed 23071262
DOI: 10.1093/annonc/mds338
https://www.ncbi.nlm.nih.gov/pubmed/23071262 (se deschide o fereastră nouă)
Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (se deschide o fereastră nouă)
Sursă: Am J Hematol 2024;99(7):1338-48.
Index: PubMed 38282557
DOI: 10.1002/ajh.27220
https://pubmed.ncbi.nlm.nih.gov/38282557/ (se deschide o fereastră nouă)